Webinars - High Point Clinical Trial Center


Non-Alcoholic Steatohepatitis (NASH): intricacies of science, epidemiology, diagnosis and clinical research in the pathway towards approval of new treatments

October 11, 2017


Nonalcoholic Steatohepatitis (NASH) is a medical condition characterized by the buildup of fat and inflammation in the liver. The incidence of this disease is on the rise and is closely related to obesity and diabetes.


Currently, there are no FDA-approved treatments for NASH and this condition has become a source of concern for the academic, medical and biopharmaceutical sectors.


This webinar will present key insight on the science and epidemiology of NASH, effective patient outreach, recruitment/screening initiatives as well as the development of novel biomarkers to overcome current diagnosis challenges associated with this chronic disease.



Dr. Margarita Nunez, Medical Director at High Point Clinical Trials Center


Dr. Nuñez is the Medical Director and Principal Investigator at High Point Clinical Trials Center. She has over 20 years of clinical research experience and has conducted over 450 trials in both early and late phase. She received her medical degree from New York Medical College and completed her residency in internal medicine at the University of South Florida College of Medicine. Upon the completion of her residency she completed a two-year fellowship in geriatric medicine and subsequently joined the faculty at the University of South Florida where she taught Internal Medicine and Geriatrics for three years. Her responsibilities at USF including being associate medical director at Hospice of Hillsborough County in addition to working at the Memory Disorder Clinic. Before entering her work in clinical trials , she practiced internal medicine at a rural health clinic in Central Florida for an additional three years before becoming Principal Investigator and Medical Director at Comprehensive Clinical Development in St. Petersburg Florida. Dr. Nuñez joined the team at High Point Clinical Trials Center in January of 2013.

Dr. Sabina Paglialunga, Metabolic and Pharmacodynamic Specialist at Celerion


Dr. Sabina Paglialunga, a Metabolic and Pharmacodynamic Specialist, joined Celerion, a full-service clinical research organization which specializes in phase I and II clinical studies, in 2015. As Celerion’s metabolic disease subject matter expert, Dr. Paglialunga works with clients from the pharmaceutical and biotech sector to provide scientific and operational support for early clinical studies with an obesity, diabetes, or fatty liver disease indication. With over 10 years of research experience, her extensive metabolic expertise is highlighted through more than 30 peer-reviewed publications.


Prior to joining Celerion, Dr. Paglialunga completed postdoctoral fellowships at the University of Waterloo (Canada), the University of Guelph (Canada), and Maastricht University (the Netherlands). Her research focused on energy metabolism and glucose homeostasis in the context of health and disease. Sabina earned her doctorate in Biochemistry at McGill University (Canada), concentrating in lipid metabolism.